SUMMARY REPORTS OF EXCHANGE SCIENTISTS

(1) Glenn E. Sheline, M.D.
Professor, Department of Radiation Oncology, Univ. of California at San Francisco, San Francisco, California

Dates of Visit: October 1-13, 1981
Host: Dr. Yoichiro Umegaki, Head, Department of Radiotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo

Summary of Activities:
Discussed plans for the agenda of the proposed meeting on Radiation Oncology to be held in fall, 1982. Also visited radiation therapy facilities in Tokyo and Chiba.



(2)
Mark Soloway, M.D.
Professor, Department of Urology, University of Tennessee Center for the Health Science, Memphis, Tennessee

Dates of Visit: November 6-15, 1981
Host:
Dr. Tadao Niijima, Professor, Faculty of Medicine, the University of Tokyo, Tokyo

Summary of Activities:
Conducted a workshop on bladder cancer treatment prior to the meeting on Treatment of Bladder Cancer held in Tokyo.



(3) Mark D. Hafermann, M.D.
Section of Radiation Oncology
The Mason Clinic, Seattle, Washington

Dates of Visit: November 6-15, 1981
Host:
Dr. Tadao Niijima, Univ. of Tokyo

Summary of Activities:
Same as (2) Dr. Mark Soloway



(4) Tetsuo Inada
Institute of Basic Medical Sciences
University of Tsukuba

Sponsor and Host Institution:
Lawrence Berkeley Laboratory, Massachusetts General Hospital, Los Alamos Scientific Laboratory
Dates of. Visit: October 26 - November 7, 1981

Summary of Activities:
The objective of study is to discuss extensively on CT aided treatment planning systems for charged particle radiotherapy with the research staff of three facilities including Massachusetts General Hospital, Lawrence Berkeley Laboratory and pi-meson Biomedical facility of University of New Mexico at Los Alamos Scientific Laboratory.
The status of the system developed at LBL was discussed with G.T.Y. Chen, at MGH with M. Goitein and L.J. Verhey and at LASL with A.R. Smith and S. Zink.
In addition, the physical, biological and clinical data for these particles which should be taken into account of treatment planning, have been presented. These were discussed with A. Chatterjee, J.T. Lyman, E.A. Blakely, T.S. Tenforde, J.R. Castro and W.B. Saunders at LBL, with A. Kohler, H. Gerchack, L. Gerwick, M. Urano and H.D. Suitat MGH and with J.F. Dicello, R.A. Hilko, A.J. Van der Kogel, M.R. Raju, H. Tokita and J. Jett at LASL.
Due to this Program the precise approach for coding the treatment planning program has been offered utilizing the relating physical and biological data.
We are planning to continue the collaboration on the development of charged particle treatment system with MGH staff. Actually, the software of the system used for the proton therapy at MGH will be transferred to Particle Radiation Medical Science Center (PARMS) of the University of Tsukuba and the pulsed proton beam at PARMS will be provided for the biological dosimetry intercomparison study which will be made between PARMS and MGH next year.
The valuable data with heavy ion beam obtained at LBL will be informed for the medical heavy ion accelerator project which is going to take-off in Japan.



(5) Hideyuki Akaza, M.D.
Lecturer, Department of Urology, Faculty of Medicine, University of Tokyo.

Dates of Visit: August 20, 1981 - June 18, 1982
Host:
Dr. Mark Soloway, Professor, Department of Urology, University of Tennessee Center for the Health Science

Summary of Activities:
Prophylactic postoperative bladder instillation of anticancer agents is effective to prevent recurrence of bladder cancer. However, sometimes the recurrent tumor grows deeply into the bladder wall invasively during a long term bladder instillation therapy. This makes cytoscopical diagnosis of tumor recurrence difficult, and moreover, makes prognosis poor.
For the purpose to study the behavior of recurrent tumor during instillation therapy, Dr. Akaza and Dr. Soloway's group have been jointly carrying studies using an animal model. The effectiveness of various anticancer agents, including the influences to the type of growth of tumor will be evaluated.
Other than above joint study, information exchange and discussions on criteria of diagnosis of bladder cancer and evaluation of the effect of treatment is done by Dr. Akaza at the clinics of the host institution and also at the Memorial Sloan-Kettering Cancer Research Institute in New York, which would be of high value at this moment when there is an attempt to organize cooperative group studies on chemotherapy of bladder cancer between the United States and Japan.